Correlation Between Inozyme Pharma and Structure Therapeutics

Can any of the company-specific risk be diversified away by investing in both Inozyme Pharma and Structure Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Inozyme Pharma and Structure Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Inozyme Pharma and Structure Therapeutics American, you can compare the effects of market volatilities on Inozyme Pharma and Structure Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Inozyme Pharma with a short position of Structure Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Inozyme Pharma and Structure Therapeutics.

Diversification Opportunities for Inozyme Pharma and Structure Therapeutics

0.3

Correlation Coefficient

Inozyme Pharma  Structure Therapeutics

Weak diversification

The 3 months correlation between Inozyme and Structure is 0.3. Overlapping area represents the amount of risk that can be diversified away by holding Inozyme Pharma and Structure Therapeutics America in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Structure Therapeutics and Inozyme Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Inozyme Pharma are associated (or correlated) with Structure Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Structure Therapeutics has no effect on the direction of Inozyme Pharma i.e., Inozyme Pharma and Structure Therapeutics go up and down completely randomly.

Pair Corralation between Inozyme Pharma and Structure Therapeutics

Given the investment horizon of 90 days Inozyme Pharma is expected to generate 1.63 times more return on investment than Structure Therapeutics. However, Inozyme Pharma is 1.63 times more volatile than Structure Therapeutics American. It trades about 0.02 of its potential returns per unit of risk. Structure Therapeutics American is currently generating about 0.01 per unit of risk. If you would invest  574.00  in Inozyme Pharma on March 11, 2025 and sell it today you would lose (175.00) from holding Inozyme Pharma or give up 30.49% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Inozyme Pharma  vs.  Structure Therapeutics America

Inozyme Pharma

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Inozyme Pharma are ranked lower than 11 (%) of all global equities and portfolios over the last 90 days. In spite of fairly unfluctuating basic indicators, Inozyme Pharma showed solid returns over the last few months and may actually be approaching a breakup point.

Structure Therapeutics

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Structure Therapeutics American are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating fundamental indicators, Structure Therapeutics may actually be approaching a critical reversion point that can send shares even higher in July 2025.

Pair Trading with Inozyme Pharma and Structure Therapeutics

The main advantage of trading using opposite Inozyme Pharma and Structure Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Inozyme Pharma position performs unexpectedly, Structure Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Structure Therapeutics will offset losses from the drop in Structure Therapeutics' long position.

The idea behind Inozyme Pharma and Structure Therapeutics American pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.